News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
781,111 Results
Type
Article (53706)
Company Profile (297)
Press Release (727094)
Multimedia
Podcasts (142)
Webinars (21)
Section
Business (214710)
Career Advice (2164)
Deals (37054)
Drug Delivery (149)
Drug Development (88454)
Employer Resources (174)
FDA (17581)
Job Trends (15970)
News (367167)
Policy (35323)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2861)
Accelerated approval (55)
ADA (46)
Adcomms (38)
Allergies (194)
Alliances (52283)
ALS (233)
Alzheimer's disease (1931)
Antibody-drug conjugate (ADC) (535)
Approvals (17958)
Artificial intelligence (752)
ASCO (341)
Autoimmune disease (351)
Automation (61)
Bankruptcy (381)
Best Places to Work (12152)
BIOSECURE Act (20)
Biosimilars (237)
Biotechnology (188)
Bladder cancer (208)
Brain cancer (81)
Breast cancer (822)
Cancer (6434)
Cardiovascular disease (547)
Career advice (1843)
Career pathing (47)
CAR-T (371)
CDC (65)
Celiac Disease (3)
Cell therapy (987)
Cervical cancer (54)
Clinical research (77059)
Collaboration (2266)
Company closure (6)
Compensation (1494)
Complete response letters (99)
COVID-19 (2953)
CRISPR (119)
C-suite (1250)
Cystic fibrosis (161)
Data (8594)
Decentralized trials (3)
Denatured (41)
Depression (191)
Dermatology (96)
Diabetes (684)
Diagnostics (7266)
Digital health (64)
Diversity (14)
Diversity, equity & inclusion (46)
Drug discovery (352)
Drug pricing (217)
Drug shortages (34)
Duchenne muscular dystrophy (313)
Earnings (94946)
Editorial (73)
Employer branding (21)
Employer resources (153)
Events (127002)
Executive appointments (1154)
FDA (21592)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (36)
Funding (1876)
Gene editing (256)
Generative AI (68)
Gene therapy (790)
GLP-1 (1221)
Government (5100)
Grass and pollen (8)
Guidances (417)
Healthcare (20330)
Hematology (197)
HIV (91)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (338)
Immuno-oncology (114)
Indications (205)
Infectious disease (3336)
Inflammatory bowel disease (237)
Inflation Reduction Act (15)
Influenza (143)
Intellectual property (314)
Interviews (338)
IPO (17171)
IRA (51)
Job creations (4121)
Job search strategy (1532)
JPM (62)
Kidney cancer (22)
Labor market (107)
Layoffs (629)
Leadership (43)
Legal (8558)
Liver cancer (108)
Longevity (36)
Lung cancer (868)
Lymphoma (463)
Machine learning (63)
Management (59)
Manufacturing (1139)
MASH (224)
Medical device (15026)
Medtech (15183)
Mergers & acquisitions (21183)
Metabolic disorders (1752)
mRNA (244)
Multiple sclerosis (202)
NASH (23)
Neurodegenerative disease (490)
Neuropsychiatric disorders (123)
Neuroscience (3635)
Neurotech (1)
NextGen: Class of 2026 (6970)
Non-profit (4812)
Now hiring (79)
Obesity (830)
Opinion (321)
Ovarian cancer (242)
Pain (281)
Pancreatic cancer (346)
Parkinson's disease (406)
Partnered (34)
Patents (629)
Patient recruitment (753)
Peanut (70)
People (63110)
Pharmaceutical (65)
Pharmacy benefit managers (34)
Phase 1 (23962)
Phase 2 (33852)
Phase 3 (25332)
Pipeline (9632)
Policy (340)
Postmarket research (2817)
Preclinical (9893)
Press Release (68)
Prostate cancer (341)
Psychedelics (67)
Radiopharmaceuticals (357)
Rare diseases (1226)
Real estate (6431)
Recruiting (70)
Regulatory (27584)
Reports (56)
Research institute (2622)
Resumes & cover letters (369)
Rett syndrome (42)
RNA editing (26)
RSV (95)
Schizophrenia (193)
Series A (316)
Series B (235)
Service/supplier (12)
Sickle cell disease (124)
Special edition (25)
Spinal muscular atrophy (181)
Sponsored (50)
Startups (3950)
State (2)
Stomach cancer (21)
Supply chain (138)
Tariffs (90)
The Weekly (99)
Vaccines (1233)
Venture capital (123)
Weight loss (561)
Women's health (137)
Worklife (20)
Date
Today (102)
Last 7 days (630)
Last 30 days (3223)
Last 365 days (31685)
2026 (15425)
2025 (31456)
2024 (36570)
2023 (41564)
2022 (52858)
2021 (57515)
2020 (56224)
2019 (49118)
2018 (37216)
2017 (34232)
2016 (34013)
2015 (39951)
2014 (33857)
2013 (29048)
2012 (31255)
2011 (32022)
2010 (30449)
Location
Africa (831)
Alabama (95)
Alaska (7)
Arizona (374)
Arkansas (16)
Asia (44120)
Australia (7377)
California (14013)
Canada (3920)
China (1536)
Colorado (608)
Connecticut (626)
Delaware (435)
Europe (97361)
Florida (2112)
Georgia (456)
Hawaii (3)
Idaho (67)
Illinois (1184)
India (95)
Indiana (633)
Iowa (23)
Japan (579)
Kansas (136)
Kentucky (52)
Louisiana (60)
Maine (76)
Maryland (1698)
Massachusetts (10108)
Michigan (385)
Minnesota (770)
Mississippi (7)
Missouri (151)
Montana (35)
Nebraska (29)
Nevada (152)
New Hampshire (91)
New Jersey (3687)
New Mexico (32)
New York (3684)
North Carolina (1859)
North Dakota (9)
Northern California (7050)
Ohio (418)
Oklahoma (24)
Oregon (45)
Pennsylvania (2786)
Puerto Rico (30)
Rhode Island (53)
South America (1210)
South Carolina (88)
South Dakota (2)
Southern California (5535)
Tennessee (224)
Texas (2260)
United States (49815)
Utah (415)
Vermont (1)
Virginia (341)
Washington D.C. (84)
Washington State (1142)
West Virginia (4)
Wisconsin (142)
Wyoming (2)
781,111 Results for "phase iii medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare disease
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
February 2, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
New Med to Manage Tourette Syndrome Shows Promise in Phase III Clinical Trial
May 26, 2026
·
4 min read
Press Releases
GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical’s Phase III Results Signal Differentiation in Weight Loss Arena
May 12, 2026
·
8 min read
Press Releases
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
June 1, 2026
·
16 min read
Alzheimer’s disease
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”
December 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 29, 2026
·
3 min read
Cardiovascular disease
Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data
Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.
November 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
June 11, 2026
·
8 min read
Press Releases
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
May 28, 2026
·
7 min read
Press Releases
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
June 1, 2026
·
7 min read
1 of 78,112
Next
